Wed, May 15, 9:15 PM (72 days ago)
Aileron Therapeutics, Inc. reported a net loss of $7.1 million for Q1 2024, an increase from the $4.8 million loss in Q1 2023. Operating expenses rose to $7.2 million, driven by a $1.7 million increase in R&D costs due to the Lung Therapeutics acquisition, and a $1.5 million rise in G&A expenses. No restructuring costs were recorded for Q1 2024. Cash and cash equivalents stood at $12.0 million as of March 31, 2024. Post-quarter, Aileron raised $17.9 million through an underwritten offering, extending its cash runway into the second half of 2025. The company is focused on advancing its clinical programs, notably LTI-03 and LTI-01, in orphan pulmonary and fibrosis indications.